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AbsTrACT
Objective to assess low-density lipoprotein cholesterol 
(lDl-c) response in patients after initiation of statins, 
and future risk of cardiovascular disease (cVD).
Methods Prospective cohort study of 165 411 primary 
care patients, from the UK clinical Practice research 
Datalink, who were free of cVD before statin initiation, 
and had at least one pre-treatment lDl-c within 12 
months before, and one post-treatment lDl-c within 24 
months after, statin initiation. Based on current national 
guidelines, <40% reduction in baseline lDl-c within 24 
months was classified as a sub-optimal statin response. 
cox proportional regression and competing-risks survival 
regression models were used to determine adjusted 
hazard ratios (hrs) and sub-hrs for incident cVD 
outcomes for lDl-c response to statins.
results 84 609 (51.2%) patients had a sub-optimal 
lDl-c response to initiated statin therapy within 24 
months. During 1 077 299 person-years of follow-up 
(median follow-up 6.2 years), there were 22 798 cVD 
events (12 142 in sub-optimal responders and 10 656 
in optimal responders). in sub-optimal responders, 
compared with optimal responders, the hr for incident 
cVD was 1.17 (95% ci 1.13 to 1.20) and 1.22 (95% 
ci 1.19 to 1.25) after adjusting for age and baseline 
untreated lDl-c. considering competing risks resulted 
in lower but similar sub-hrs for both unadjusted (1.13, 
95% ci 1.10 to 1.16) and adjusted (1.19, 95% ci 1.16 
to 1.23) cumulative incidence function of cVD.
Conclusions Optimal lowering of lDl-c is not achieved 
within 2 years in over half of patients in the general 
population initiated on statin therapy, and these patients 
will experience significantly increased risk of future cVD.
InTrOduCTIOn
Cardiovascular disease (CVD) remains the leading 
cause of death globally.1 The positive correla-
tion between the incidence of CVD and levels 
of low-density lipoprotein cholesterol (LDL-C) 
concentration has been well-established.2 Statins 
are recognised as being effective in lowering choles-
terol and reducing the risk of future CVD events for 
both primary or secondary prevention.3 
Following a meta-analysis of cholesterol treat-
ment trials,4 the percentage reductions in LDL-C 
achieved by specific statins (and their doses) have 
been established from the data of patients in whom 
statins reduced CVD events. Accordingly, national 
guidelines in the USA and UK recommend intended 
LDL-C reduction targets for statin therapy to reduce 
CVD.5 6 The 2013 American College of Cardiology/
American Heart Association (ACC/AHA) guidelines 
suggested a fixed dose (or intensity) of statin for 
each risk category, with an intended LDL-C reduc-
tion of 30–49% and ≥50% for moderate and 
high intensity statins, respectively.6 The National 
Institute for Health and Care Excellence (NICE) 
guidelines in the UK aim for >40% reduction in 
non-HDL-C.5
Both individual biological and genetic variability 
in LDL-C response to statin therapy,7 as well as vari-
ation in adherence, have been identified.8 However, 
there is limited evidence on variation in LDL-C 
response in the general population for patients initi-
ated on statins for primary prevention of CVD.
In this large, prospective open population cohort 
study, we sought to assess differences in LDL-C 
response in primary care patients initiated on statins 
and their impact on future CVD events.
MeThOds
data source
This prospective cohort study used the UK Clin-
ical Practice Research Datalink (CPRD) of primary 
care electronic health records, linked to Hospital 
Episode Statistics (HES) and Office for National 
Statistics (ONS) data. HES provides information 
on all hospital admissions and the ONS records 
cause-specific mortality for all deaths in England 
and Wales. The CPRD database contains anony-
mised patient data from 681 family physician prac-
tices (approximately 8% of the UK population) and 
is broadly representative of the general population 
in terms of age, sex and ethnicity. CPRD has good 
ascertainment of major diagnoses such as hyperten-
sion and other chronic conditions, and has provided 
a key source of evidence for major research.9 This 
study was approved by the Independent Scientific 
Advisory Committee for the Medicines and Health-
care Products Regulatory Agency database research 
(ISAC Protocol 17_200R).
study population
This cohort study comprised 183 213 patients 
(males and females) initiated on statin therapy 
between 3 September 1990 and 7 June 2016 identi-
fied from the CPRD database. Patients were eligible 
for inclusion if they were registered with their family 
practice for at least 12 months, and their electronic 
health records met CPRD quality control.9 Patients 
had at least two recorded LDL-C measurements (at 
least one measurement within 12 months before 
statin initiation and one measurement within 24 
months after statin initiation). All individuals who 
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had a CVD event any time before initiating statin therapy were 
excluded.
exposure
Based on current NICE Cardiovascular Disease Guidelines 
(CG181),5 patients on treatment with statins for primary preven-
tion of CVD who failed to achieve >40% reduction in untreated 
baseline LDL-C record within the first 24 months were defined 
as sub-optimal responders. The untreated baseline LDL-C 
record used was the most recent within 12 months before or at 
the initiation of statin therapy. For post-treatment response, the 
most recent LDL-C record at or closest to 24 months was used. 
While a 12 month follow-up period to gauge treatment response 
is recommended by national guidelines, 24 months was consid-
ered a more pragmatic timeframe to ascertain post-treatment 
LDL-C in this study. In general practice there is typically slippage 
on the 12 months follow-up cholesterol test and patient review. 
The 24 month time point ensures all follow-up cholesterols are 
captured.
Outcomes
CVD events were defined as: coronary heart disease (CHD), 
stroke/transient ischaemic attack (TIA), peripheral vascular 
disease (PVD), or CVD-related death. Follow-up for incident 
CVD was from 24 months after first prescription of any statin, 
to first record of either a CVD event, non-CVD-related death, 
transfer out of the practice, or the end of CPRD data collection. 
Patients with a recorded CVD event within the 24 month expo-
sure period were excluded from the analyses.
Evidence from both randomised trials and cohort studies show 
the full effect of serum cholesterol reduction on risk of CVD is 
not achieved until after the first 2 years of statin initiation.10 
Therefore, any inclusion of CVD outcome events in the first 2 
years (before the full effect of reducing serum LDL-C concen-
tration is achieved) would underestimate the full effect.3 Thus, 
individuals with CVD events in the first 2 years (our defined 
exposure period) were excluded from analysis to avoid underes-
timation of our results.
CVD events were identified from primary and secondary care 
records and the ONS death registry. In CPRD, ‘medcodes’ are 
mapped equivalents of the widely used Read clinical coding 
system in primary care in the UK. Codes for CVD events in 
CPRD have been reported previously.11 International Classifi-
cation of Diseases, 10th revision (ICD-10) codes were used to 
identify CVD-related events in HES and ONS. In HES and ONS, 
a CVD event was recorded if it was coded as the primary diag-
nosis across a hospitalisation or the underlying cause of death, 
respectively.
baseline cardiovascular risk factors
We assessed baseline covariates (online supplementary appendix 
1) as potential confounders for the relation between statin therapy 
response and future CVD event. The most recent values within 
12 months before the study entry date (first prescribed statin 
date) were used for smoking status, alcohol misuse, systolic and 
diastolic blood pressures, prescription of medications and medi-
cation count at baseline. Year of statin initiation (accounting for 
time differences), the number of LDL-C measurements recorded 
(accounting for frequency of monitoring) and change of statin 
potency within the exposure period were also considered as 
potential confounders. All other covariates were based on the 
latest record before the study entry date. Deprivation was based 
on the English Index of Multiple Deprivation 2015 (IMD)12 
linked to patient postcode, with patients grouped by fifths. The 
IMD is a weighted aggregate for the local neighbourhood (mean 
population 1500) of deprivation across seven domains: income; 
employment; health deprivation and disability; education, skills, 
and training; barriers to housing and services; living environ-
ment; and crime.
statistical analysis
To obtain estimates of the association between sub-optimal 
cholesterol response to statin therapy and the incidence of CVD 
in our cohort, we performed Cox proportional hazards regres-
sion analysis, adjusting for significant baseline covariates. In this 
analysis, informative censoring of the survival time was taken 
into account by considering patients transferring out of the prac-
tice and death as competing risks for incident CVD. We there-
fore performed a competing-risk analysis which provided the 
cause-specific (or sub-) hazard ratio (HR) and used it to calcu-
late the cumulative incidence of the CVD outcomes of interest. 
We similarly adjusted for significant covariates for the compet-
ing-risks regression based on Fine and Grey’s13 proportional 
sub-hazards model.
We carried out a sensitivity analysis restricting the cohort to 
only patients with post-treatment LDL-C after at least 3 months 
of statin initiation (in line with the NICE lipid guideline recom-
mendation of first monitoring LDL-C at 3 months from statin 
initiation).
Multiple imputation by chained equations procedure in 
Stata14 was used to estimate missing values for body mass index 
(BMI) and systolic and diastolic blood pressures. All other 
patient variables were included in the imputation models to 
create 10 imputed datasets. The change-in-estimate criterion15 
was used to determine significant covariates. Covariates were 
considered significant if they altered the unadjusted expo-
sure-outcome effect by 5% or more.
Further analysis was performed to assess the relationship 
between LDL-C reduction as a continuous variable and the risk 
of CVD in the population of patients who had a reduction in 
LDL-C over the follow-up period.
All statistical analyses were performed using Stata 15.1 
(StataCorp LP). Values of p<0.05 were considered to be statis-
tically significant.
resulTs
From the 207 230 patients identified from CPRD, 17 872 
patients were excluded due to having a prior record of a CVD 
event. There were 23 947 patients with a CVD event within 
24 months of initiating therapy (exposure period) and hence 
they were excluded from the analysis (online supplementary 
appendix 2). The cohort, therefore, included 165 411 eligible 
patients initiating statin therapy. There were 84 609 (51.2%) 
patients with a sub-optimal LDL-C response at 24 months after 
initiating statin therapy. The mean age at therapy initiation was 
62.4 years and 48.6% of the study population were women. The 
median follow-up time was 5.9 and 6.5 years for sub-optimal 
and optimal statin responders, respectively. A higher proportion 
of patients with a sub-optimal response were prescribed lower 
potency statins compared with those with an optimal response. 
There were differences between groups by age, gender, depri-
vation, smoking status, baseline LDL-C and statin potency 
(p<0.05). Table 1 shows the baseline characteristics of the entire 
cohort and online supplementary appendix 3 shows the baseline 
characteristics stratified by year of statin initiation.
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Table 1 Characteristics of eligible patients being treated with statins and free from cardiovascular disease at baseline. Patients are stratified by 
response to statin (based on LDL-C measurement) 24 months after initiation of statin therapy
Characteristics
Total number (%) Optimal statin responders, n (%)
sub-optimal statin 
responders, n (%)
165 411 (100) 80 802 (48.85) 84 609 (51.15)
Follow-up time (years) Median (IQR) 6.2 (3.4–9.3) 6.5 (3.6–9.6) 5.9 (3.3–9.1)
Females No. (%) 80 370 (48.6) 40 739 (50.4) 39 631 (46.8)
Age (years) Mean (SD) 62.4 (11.8)* 63.6 (11.4) 61.3 (12.0)
Baseline LDL-C (mmol/L) Mean (SD) 4.1 (1.1) 4.4 (1.1) 3.8 (1.1)
Post-treatment LDL-C within 24 months (mmol/L) Mean (SD) 2.6 (1.0) 2.1 (0.6) 3.1 (1.0)
BMI (kg/m2) Mean (SD) 29.1 (5.7)† 29.0 (5.5) 29.3 (5.9)
Systolic blood pressure (mm Hg) Mean (SD) 143 (19)‡ 144 (20) 141 (19)
Diastolic blood pressure (mm Hg) Mean (SD) 83 (11)§ 83 (11) 82 (11)
Alcohol misuse No. (%) 1231 (0.7) 493 (0.6) 738 (0.9)
Smoking
 Non-smoker No. (%) 2561 (1.6) 1259 (1.6) 1302 (1.5)
 Ex-smoker 1838 (1.1) 881 (1.1) 957 (1.1)
 Smoker 2003 (1.2) 868 (1.1) 1135 (1.3)
 Unknown status 159 009 (96.1) 77 794 (96.3) 81 215 (96.0)
 Index of Multiple Deprivation (patients)
 1 No. (%) 21 945 (22.9) 11 044 (23.8) 10 901 (22.1)
 2 21 142 (22.1) 10 467 (22.6) 10 675 (21.6)
 3 19 224 (20.1) 9288 (20.0) 9936 (20.1)
 4 18 186 (19.0) 8583 (18.5) 9603 (19.4)
 5 15 291 (16.0) 6990 (15.1) 8301 (16.8)
Comorbidities (before first statin)
Diabetes
 Non-diabetic No. (%) 137 984 (83.42) 67 739 (83.8) 70 245 (83.0)
 Poorly-controlled diabetic 9246 (5.6) 4351 (5.4) 4895 (5.8)
 Well-controlled diabetic 3253 (2.0) 1698 (2.1) 1555 (1.8)
 Diabetic control status unknown 14 928 (9.0) 7014 (8.7) 7914 (9.4)
Dyslipidaemias No. (%) 13 445 (8.1) 6351 (7.9) 7094 (8.4)
Atrial fibrillation No. (%) 4849 (2.9) 2473 (3.1) 2376 (2.8)
Chronic kidney disease No. (%) 4469 (2.7) 2264 (2.8) 2205 (2.6)
Family history of cardiovascular disease No. (%) 17 522 (10.6) 8495 (10.5) 9027 (10.7)
Family history of hyperlipidaemia No. (%) 389 (0.2) 183 (0.2) 206 (0.2)
Treated hypertension No. (%) 43 242 (26.1) 22 711 (28.1) 20 531 (24.3)
Hypothyroidism No. (%) 6867 (4.2) 3492 (4.3) 3375 (4.0)
Liver disease No. (%) 1556 (0.9) 729 (0.9) 827 (1.0)
Migraine No. (%) 3612 (2.2) 1800 (2.2) 1812 (2.1)
Nephrotic syndrome No. (%) 111 (0.1) 50 (0.1) 61 (0.1)
Rheumatoid arthritis No. (%) 1465 (0.9) 718 (0.9) 747 (0.9)
Severe mental illness No. (%) 710 (0.4) 350 (0.4) 360 (0.4)
Systemic lupus erythematosus No. (%) 181 (0.1) 77 (0.1) 104 (0.1)
Medications (prescribed within 12 months before first statin)
Medication count Median (IQR) 6 (3–9) 6 (3–9) 6 (3–9)
Antipsychotics No. (%) 6919 (4.2) 3634 (4.5) 3285 (3.9)
Other lipid lowering medication No. (%) 670 (0.4) 244 (0.3) 426 (0.5)
Oral corticosteroids No. (%) 6760 (4.1) 3193 (4.0) 3567 (4.2)
Potency of initial statin prescribed
 Low No. (%) 39 343 (23.8) 14 674 (18.2) 24 669 (29.2)
 Medium 117 264 (70.9) 61 511 (76.1) 55 753 (65.9)
 High 8804 (5.3) 4617 (5.7) 4187 (5.0)
Missing data
Missing BMI No. (%) 73 801 (44.6) 37 132 (46.0) 36 669 (43.3)
Missing systolic blood pressure No. (%) 19 383 (11.7) 8357 (10.3) 11 026 (13.0)
Missing diastolic blood pressure No. (%) 19 322 (11.7) 8317 (10.3) 11 005 (13.0)
*Mean (SD) for all 165 411 patients.
†Mean (SD) for 91 610 (optimal: 43 670; sub-optimal: 47 940) patients with baseline body mass index record.
‡Mean (SD) for 146 028 (optimal: 72 445; sub-optimal: 73 583) patients with baseline systolic blood pressure record.
§Mean (SD) for 146 089 (optimal: 72 485; sub-optimal: 73 604) patients with baseline diastolic blood pressure record.
BMI, body mass index; LDL-C, low-density lipoprotein cholesterol.
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Figure 1 Venn diagram showing the incident CVD events recorded 
in each database used to ascertain CVD outcomes: primary care data 
(CPRD) 16 080; secondary care data (HES) 9834; mortality registry (ONS) 
4350. The overlap of incident CVD events in the three datasets are also 
indicated: 713 in all three databases. CVD, cardiovascular disease; CPRD, 
Clinical Practice Research Datalink; HES, Hospital Episode Statistics; 
ONS, Office for National Statistics.
Figure 2 The cumulative incidence curve demonstrated that patients with a sub-optimal LDL-C response to statin therapy were associated with a 
higher risk of CVD events than patients with an optimal response during the follow-up period, with an adjusted HR of 1.22 (95% CI 1.19 to 1.25). 
Adjusted for age and baseline LDL-cholesterol level. CVD, cardiovascular disease; HR, hazard ratio; LDL-C, low-density lipoprotein cholesterol.
Incident cardiovascular events
Combining primary care data from CPRD, mortality data 
from ONS and hospitalisation data from HES, incident CVD 
events were recorded in 22 798 (13.8%) patients: coronary 
artery disease, 13 142 (8.0%); stroke/TIA, 4865 (2.9%); PVD, 
3097 (1.9%); CVD-related death, 1694 (1.0%). Incident CVD 
events were recorded exclusively in CPRD in 10 928 (6.6%) of 
patients. An additional 4080 (2.5%) and 2333 (1.4%) incident 
events were obtained from linkages to HES and ONS datasets, 
respectively. Some incident CVD events were recorded in more 
than one database (figure 1), with an overlap for all three linked 
databases in 713 (0.4%) patients.
Overall incidence of cardiovascular events
During 1 077 299 person-years of follow-up, there were 22 798 
CVD events (12 142 in sub-optimal responders and 10 656 in 
optimal responders). The rate of CVD was 22.6 and 19.7 per 
1000 person-years for sub-optimal and optimal responders, 
respectively. Patients with a sub-optimal response, compared 
to  those with an optimal response, were significantly more 
likely to have an incident CVD event (crude HR 1.17, 95% 
CI 1.13 to 1.20; p<0.001). After adjusting for age and base-
line untreated LDL-C value, the risk of CVD remained signifi-
cantly greater in sub-optimal responders compared with optimal 
responders (adjusted HR 1.22, 95% CI 1.19 to 1.25; p<0.001). 
A competing risk approach resulted in lower but similar sub-HRs 
for incidence of CVD for both unadjusted (1.13, 95% CI 1.10 
to 1.16; p<0.001) and adjusted (1.19, 95% CI 1.16 to 1.23; 
p<0.001) cumulative incidence function, as shown in figure 2.
Incidence of constituent CVd outcomes
There was a significantly increased risk of coronary artery 
disease, PVD and CVD-related death in patients with a sub-op-
timal response compared with those with an optimal response in 
the unadjusted models using both Cox regression and competing 
risk analysis. In the adjusted models, the increased risk remained 
significant for all the outcomes including stroke/TIA using both 
approaches. Although the competing risk approach resulted in 
lower estimates of incidence/risk, the adjusted analysis remained 
significant (table 2). A total of 15 630 patients had a post-treat-
ment LDL-C record within 3 months of statin initiation. 
When these patients were excluded (in a sensitivity analysis – 
online supplementary appendix 4), the incidence of overall CVD 
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Table 2 Effect estimates for association between sub-optimal LDL-C response at 24 months to initiated statin therapy and the risk of incident 
cardiovascular events using different statistical approaches (n=165 411)
Group
number of 
CVd events
rate of CVd 
events (per 1000 
person-years)
Crude/unadjusted models Adjusted models
Cox regression
Competing-risks 
survival regression Cox regression
Competing-risks 
survival regression
hr (95% CI) shr (95% CI) hr (95% CI) shr (95% CI)
Overall CVD-
related event*
Optimal 10 656 19.7 1 1 1 1
Sub-optimal 12 142 22.6 1.17 (1.13 to 1.20) 1.13 (1.10 to 1.16) 1.22 (1.19 to 1.25) 1.19 (1.16 to 1.23)†
CAD‡ Optimal 5986 11.1 1 1 1 1
Sub-optimal 7156 13.3 1.22 (1.17 to 1.26) 1.18 (1.14 to 1.22) 1.30 (1.25 to 1.34) 1.23 (1.19 to 1.27) §
Stroke/TIA* Optimal 2387 4.4 1 1 1 1
Sub-optimal 2478 4.6 1.07 (1.01 to 1.13) 1.02 (0.96 to 1.08) 1.15 (1.08 to 1.22) 1.10 (1.04 to 1.17)¶
PVD* Optimal 1462 2.7 1 1 1 1
Sub-optimal 1635 3.0 1.14 (1.07 to 1.23) 1.09 (1.02 to 1.17) 1.16 (1.08 to 1.25) 1.12 (1.04 to 1.21)**
CVD-related 
death*
Optimal 821 1.5 1 1 1 1
Sub-optimal 873 1.6 1.09 (0.99 to 1.20) 1.04 (0.95 to 1.15) 1.25 (1.13 to 1.38) 1.21 (1.09 to 1.34)††
Cox regression provides hazard ratio (HR) whereas competing-risks survival regression (Fine-Grey model) provides sub-hazard ratio (sHR).
*The multivariable Cox and competing-risk regression models for overall CVD-related events, stroke/TIA, PVD and CVD-related deaths were adjusted for age and baseline LDL-C 
value.
†Competing risks for overall CVD-related event were non-CVD-related death and transfer out of practice.
‡The multivariable Cox and competing-risk regression models for CAD were adjusted for age.
§Competing risks for CAD model were death, transfer out of practice, stroke/TIA and PVD.
¶Competing risks for stroke/TIA model were death, transfer out of practice, CAD and PVD.
**Competing risks for PVD model were death, transfer out of practice, CAD and stroke/TIA.
††Competing risks for CVD-related death were non-CVD-related death, transfer out of practice, CAD, stroke/TIA and PVD.
CAD, coronary artery disease; CPRD, Clinical Practice Research Datalink; CVD, cardiovascular disease; HES, Hospital Episodes Statistics, LDL-C, low-density lipoprotein cholesterol; 
ONS, Office of National Statistics; PVD, peripheral vascular disease; TIA, transient ischaemic attack. 
and constituents of CVD remained significant with similar inci-
dence rates.
In patients with a reduction in LDL-C within 24 months 
(n=146 355), 65 862 (45%) had a sub-optimal LDL-C response 
(online supplementary appendix 5). A unit reduction of 1 mmol/L 
LDL-C was found to be associated with a significant decrease 
in any CVD (OR 0.94, 95% CI 0.91 to 0.98) in patients with 
sub-optimal decreases in LDL-C. In this group, the decreased 
risk remained significant for only stroke/TIA and was not signif-
icant for other constituent CVD outcomes.
However, in patients with an optimal response, an even 
greater protective effect of LDL-C reduction and future CVD 
was seen (OR 0.87, 95% CI 0.84 to 0.90). The decreased risk 
remained significant for all constituent CVD outcomes.
dIsCussIOn
Principal findings
This large prospective population cohort study has found that 
over half of patients started on statin therapy for primary 
prevention of CVD did not experience an optimal therapeutic 
reduction of their LDL-C 24 months after therapy initiation. 
Moreover, taking into account age and baseline LDL-C values, 
the incidence and risk of future CVD (coronary artery disease, 
stroke/TIA, PVD and CVD-related death) in these patients was 
significantly greater compared to those with an optimal thera-
peutic response. The study also highlights the benefit of reducing 
LDL-C to optimal values, which would lead to better CVD 
outcomes for patients currently on statins.
Comparison with other literature/studies
Our present findings, at a general population level, are consis-
tent with inter-individual variation in response to statin therapy 
found in a smaller cross-sectional study of 22 063 patients, with 
up to a half (48.2%) of those prescribed statins not achieving 
their lipid reduction goals.16 As a result, despite statin therapy, 
many individuals remain at a much higher risk of atherosclerotic 
CVD, as shown in our study. Multiple patient characteristics, 
including sex, age, smoking status, body weight, diet and phys-
ical activity, have been reported to contribute to variations in 
statin-induced LDL-C reduction, but the impact of these factors 
is considered to be modest.17 18 However, variations in indi-
vidual patient genotypes,7 and probably non-adherence,19 may 
be an important explanation for this phenomenon.
A number of cross-sectional (single-point) observational 
studies have investigated the prevalence of lipid disorders and 
statin use.20 21 However, these studies have used differing meth-
odologies and data collection systems, or have been limited to 
specific populations (inherited lipid disorders such as familial 
hypercholesterolaemia) and thus their findings are not gener-
alisable to the general population. In addition, the associa-
tion between the inter-individual variations and future CVD 
outcomes were not explored.20
Meta-analysis of trial data supports the results of our study 
in suggesting that achieving optimal LDL-C reduction can 
provide cardiovascular benefits.22 However, the results from 
controlled trial settings cannot necessarily be readily extrap-
olated to treatment experience for patients in routine clinical 
practice.
Given that success in improving healthcare delivery is in 
part dependent on accurate estimation and reporting of the 
incidence and risk of various outcomes, it is imperative that 
future studies adequately account for the competing risks in 
similar analyses. For example, in a study using data from the 
European Renal Association-European Dialysis and Transplant 
Association (ERA-EDTA) Registry, the Kaplan-Meier method, 
compared with the competing risk method, overestimated 
the probabilities of the study outcomes at both 2 and 5 years' 
follow-up.23
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Key messages
What is already known on this subject?
 ► Statins, the most widely prescribed class of drugs, are 
associated with variations in cholesterol response.
What might this study add?
 ► This study provides ‘real world evidence’ that 50% of patients 
started on statins do not derive the intended therapeutic 
benefit from them, significantly increasing their risk of future 
cardiovascular disease.
how might this impact on clinical practice?
 ► These findings contribute to the debate on the effectiveness 
of statin therapy and highlight the need for personalised 
medicine in lipid management for patients.
Clinical implications
Statins rank among the most commonly prescribed drug classes. 
Recent revisions of clinical guidelines for CVD risk reduction 
have significantly expanded the population of patients deemed 
eligible for statin therapy.5 6 24 As the high levels of statin 
prescribing in the UK are similar to those in the USA and many 
other countries,25 the findings should translate well, particularly 
to other similar western populations. There was a substantial 
duration of follow-up for outcomes. A wide range of potential 
confounders were also evaluated and adjusted for in the analyses.
Based on evidence from clinical trial settings, the response of 
patients to statins varies widely, with reductions in LDL-C values 
following the administration of statins ranging from 5–70%.26 
In our study using a large general population reflecting routine 
practice, over half of the patients had a sub-optimal LDL-C 
response.
Currently, there is no management strategy in clinical practice 
which takes into account patient variations in LDL-C response,27 
and no guidelines for predictive screening before commence-
ment of statin therapy. Validated clinical decision tools which 
can predict cholesterol response to statins, or to non-statin 
drugs, with interventions to help clinicians to tailor and optimise 
statin treatments for individual patients are needed.
strength and limitations
To our knowledge, this study is the first large prospective general 
population study to quantify the variability in LDL-C response 
to statins and its impact on future CVD events. Strengths of the 
study include its prospective design, large sample size, use of 
multiple data linkages to maximise ascertainment of all CVD 
outcomes, and methods of analysis which account for competing 
risk events.28 The cohort was derived from high quality primary 
and secondary care care databases9 which are broadly repre-
sentative of the general UK population. These characteristics 
enhance the external validity and generalisability of our findings. 
Future research should look to validate or replicate our findings 
in other databases or other populations.
Some limitations of this study are recognised. Despite inves-
tigating the potential effects of a wide range of confounders in 
this study, it is recognised that the use of CPRD, in common 
with other large population database research, precludes capture 
of all possible confounders. The effect of patient non-adherence 
to therapy could not be accounted for, but the findings never-
theless reflect real-world experience of treatment responses 
and outcomes for a large general population over time. This 
limitation, together with others including ascertainment and 
information bias, and potential bias due to missing data, are 
acknowledged and shared in common with other large popula-
tion studies and database analyses.29 30 We used well-established 
coded definitions of outcomes and diagnoses, with two clinicians 
reviewing all definitions. However, we acknowledge the lack 
of formal adjudication of recorded outcomes and diagnosis, 
which was not possible given that databases are anonymised for 
research. Finally, alternative methods of analysis such as the use 
of instrumental variables to proxy unmeasured variables such as 
medication adherence, which our analysis could not account for, 
could be considered within a mediation analysis framework.
COnClusIOn
Over half of the patients in the large general population studied 
did not experience an optimal reduction in their LDL-C, 24 
months after starting statin therapy. These patients had a signifi-
cantly increased risk of future CVD (coronary artery disease, 
stroke/TIA, PVD) compared with those with an optimal choles-
terol response.
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